Immunomodulatory Agents for Treatment of Patients with Inflammatory Bowel Disease (Review safety of anti-TNF, Anti-Integrin, Anti IL-12/23, JAK Inhibition, Sphingosine 1-Phosphate Receptor Modulator, Azathioprine / 6-MP and Methotrexate)-Reference-Cited by-同舟云学术

Immunomodulatory Agents for Treatment of Patients with Inflammatory Bowel Disease (Review safety of anti-TNF, Anti-Integrin, Anti IL-12/23, JAK Inhibition, Sphingosine 1-Phosphate Receptor Modulator, Azathioprine / 6-MP and Methotrexate)

Published:2021-12 Issue:12 Volume:23 Page:
ISSN:1522-8037
Container-title:Current Gastroenterology Reports
language:en
Short-container-title:Curr Gastroenterol Rep

Author:

Sattler Lindsey^ORCID,Hanauer Stephen B,Malter Lisa

Publisher

Springer Science and Business Media LLC

Subject

Gastroenterology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s11894-021-00829-y.pdf

Reference69 articles.

1. Dahlhamer JM, Zammitti EP, Ward BW, Wheaton AG, Croft JB. Prevalence of Inflammatory Bowel Disease Among Adults Aged >/=18 Years - United States, 2015. MMWR Morb Mortal Wkly Rep. 2016;65(42):1166-9. https://doi.org/10.15585/mmwr.mm6542a3.

2. Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG Clinical Guideline: Management of Crohn's Disease in Adults. Am J Gastroenterol. 2018;113(4):481–517. https://doi.org/10.1038/ajg.2018.27.

3. Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG Clinical Guideline: Ulcerative Colitis in Adults. Am J Gastroenterol. 2019;114(3):384–413. https://doi.org/10.14309/ajg.0000000000000152.

4. Mao EJ, Hazlewood GS, Kaplan GG, Peyrin-Biroulet L, Ananthakrishnan AN. Systematic review with meta-analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn's disease and ulcerative colitis. Aliment Pharmacol Ther. 2017;45(1):3–13. https://doi.org/10.1111/apt.13847.

5. Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Price S, et al. Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT registry. Am J Gastroenterol. 2012;107(9):1409–22. https://doi.org/10.1038/ajg.2012.218.

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Umbilical cord mesenchymal stem cells in ulcerative colitis treatment: efficacy and possible mechanisms;Stem Cell Research & Therapy;2024-09-02

2. Antibodies Targeting the Tumor Necrosis Factor-Like Ligand 1A in Inflammatory Bowel Disease: A New Kid on the (Biologics) Block?;Digestion;2024-07-26

3. TNF-α-positive patients with recurrent pregnancy loss: The etiology and management;Technology and Health Care;2024-07-16

4. Immunity in digestive diseases: new drugs for inflammatory bowel disease treatment—insights from Phase II and III trials;Journal of Gastroenterology;2024-07-09

5. Systematic Review with Meta-analysis: Efficacy and Safety of Upadacitinib in Managing Moderate-to-Severe Crohn’s Disease and Ulcerative Colitis;Clinical Drug Investigation;2024-05-23